Advench Pharmaceutical Private Limited

Easy Six Vaccine, developed by Panacea Biotec Ltd., is a comprehensive hexavalent vaccine designed to protect infants and children against six serious infectious diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis (polio), hepatitis B, and Haemophilus influenzae type b (Hib).

This combination vaccine simplifies the immunization schedule by reducing the number of injections required, thereby improving compliance and convenience. It is administered via a single intramuscular or intradermal injection, typically starting at 6 weeks of age, with subsequent doses at 10 and 14 weeks, followed by a booster dose in the second year of life.

The vaccine is presented in a 0.5 ml prefilled syringe, ensuring accurate dosing and ease of administration. It should be stored under refrigeration at 2–8°C and protected from freezing to maintain its efficacy.

Common side effects may include mild local reactions at the injection site, such as redness, swelling, or pain, as well as fever, irritability, and fatigue. These reactions are generally transient and resolve without the need for medical intervention.

Easy Six Vaccine is an essential component of the national immunization program, contributing to the reduction of vaccine-preventable diseases in the pediatric population.

Rabivax-S is a highly effective inactivated rabies vaccine developed by Serum Institute of India Pvt. Ltd. It is designed to provide active immunization against the rabies virus, a fatal infection transmitted through bites or scratches from infected animals.

The vaccine is administered via intramuscular or intradermal injection, typically in the deltoid muscle for adults and older children, or in the anterolateral thigh for infants and young children. The standard vaccination schedule involves a series of doses administered on days 0, 3, 7, 14, and 28 for post-exposure prophylaxis, and a series of 3 doses on days 0, 7, and 21 for pre-exposure prophylaxis. A booster dose is recommended every 1–3 years depending on the level of risk and exposure.

Rabivax-S is suitable for use in both children and adults, including pregnant and lactating women, when the risk of rabies exposure is significant. It is contraindicated in individuals with a known hypersensitivity to any component of the vaccine.

Common side effects may include pain, redness, or swelling at the injection site, headache, fever, muscle aches, and nausea. These reactions are generally mild and transient.

Synflorix Pneumococcal Conjugate Vaccine (PCV10) is a widely used pediatric vaccine that provides active immunization against invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae. Manufactured by GlaxoSmithKline Biologicals S.A. in Belgium, this vaccine is formulated using 10 pneumococcal serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F). These antigens are conjugated to carrier proteins such as protein D of Haemophilus influenzae, tetanus toxoid, and diphtheria toxoid to generate a stronger and longer-lasting immune response in young children.

Synflorix is presented as a 0.5 mL sterile suspension in a pre-filled glass syringe, available in cartons of 1 syringe (with or without attached needle). Multipack options with 10 syringes per carton are also available, making it suitable for hospitals, clinics, and immunization programs.

The vaccine is administered by intramuscular injection into the anterolateral thigh in infants or deltoid muscle in older children. It is indicated for infants and children from 6 weeks up to 5 years of age. The recommended schedule may be a 2+1 or 3+1 dosing regimen, depending on national guidelines.

With a shelf life of 36 months, Synflorix must be stored in the cold chain between 2–8 °C and never frozen. It is an essential component of pediatric vaccination programs worldwide.

Vaxiflu Influenza Vaccine is an inactivated split-virion seasonal influenza vaccine developed and manufactured by Zydus Cadila (Cadila Healthcare Ltd.), India. It provides active immunization against influenza A and B virus subtypes recommended by the World Health Organization (WHO) for each flu season.

The vaccine is supplied in a 0.5 mL pre-filled syringe or glass vial, designed for a single-dose administration. Packaging includes individual units or cartons of 10 syringes/vials, making it suitable for clinics, hospitals, and immunization drives. Each dose contains purified hemagglutinin antigens from influenza A (H1N1 and H3N2) and influenza B strains, split and inactivated to ensure safety while retaining immunogenicity.

Vaxiflu is indicated for children, adults, and elderly individuals, particularly those at higher risk of influenza complications such as patients with chronic diseases, healthcare workers, and the immunocompromised. The vaccine is administered by intramuscular or deep subcutaneous injection. Annual vaccination is recommended to maintain protection, as influenza virus strains undergo frequent antigenic changes.

With a shelf life of 12–24 months, Vaxiflu must be stored in the cold chain between 2–8 °C and should never be frozen. It is a widely used vaccine in India for seasonal influenza prevention.

Infanrix is a combination vaccine manufactured by GlaxoSmithKline (GSK) to protect children against Diphtheria, Tetanus, Pertussis (whooping cough), Hepatitis B, and Poliomyelitis (DTaP-HepB-IPV). This hexavalent vaccine is formulated to reduce the number of injections required in early childhood immunization programs. Each 0.5 mL dose contains purified diphtheria and tetanus toxoids, inactivated pertussis antigens, recombinant hepatitis B surface antigen, and inactivated poliovirus types 1, 2, and 3. Infanrix stimulates the immune system to produce protective antibodies against all five diseases, helping prevent severe illness, hospitalization, and potential life-threatening complications. The vaccine is indicated for infants from 6 weeks of age, with administration following national immunization schedules. It is given intramuscularly (IM), usually in the anterolateral thigh or deltoid muscle depending on age. Infanrix has demonstrated excellent immunogenicity and a favorable safety profile in clinical studies. Mild local reactions, low-grade fever, or irritability may occur but generally resolve quickly. The vaccine must be stored at 2–8 °C and protected from freezing. Supplied in prefilled syringes or vials, Infanrix is suitable for routine pediatric vaccination and catch-up schedules in both public health programs and private healthcare settings.tion.

• Active Ingredient: 150 mcg Anti-D Immunoglobulin per dose
• Purpose: Prevents Rh immunization in Rh-negative mothers after exposure to Rh-positive fetal blood
• Dosage Form: Injectable, intramuscular administration
• Indication: Used for Rh prophylaxis during pregnancy, postpartum, or after sensitizing events
• Benefits: Helps prevent hemolytic disease of the newborn (HDN)
• Packaging: Supplied in pre-filled syringes or vials
• Storage: Refrigerate at 2°C – 8°C; do not freeze
• Administration: To be used under medical supervision

• Active Ingredient: 40 mcg Darbepoetin Alfa per dose
• Purpose: Treats anemia associated with chronic kidney disease (CKD) and chemotherapy
• Mechanism: Stimulates the production of red blood cells in the bone marrow
• Administration: Subcutaneous or intravenous injection under medical supervision
• Dosage: Determined by physician based on hemoglobin levels
• Packaging: Available in pre-filled syringe or vial for accurate dosing
• Storage: Store refrigerated at 2°C – 8°C; do not freeze.

• Active Ingredient: 40 mcg Darbepoetin Alfa per dose
• Purpose: Treats anemia associated with chronic kidney disease (CKD) and chemotherapy
• Mechanism: Stimulates red blood cell production in the bone marrow
• Administration: Subcutaneous or intravenous injection under medical supervision
• Dosage: Determined by physician based on hemoglobin levels
• Packaging: Available in pre-filled syringe or vial for accurate dosing
• Storage: Store refrigerated at 2°C – 8°C; do not freeze
• Safety: To be used strictly under medical supervision

• Active Ingredient: 60 mcg Darbepoetin Alfa per dose
• Purpose: Treats anemia associated with chronic kidney disease (CKD) and chemotherapy
• Mechanism: Stimulates red blood cell production in the bone marrow
• Dosage Form: Injectable, subcutaneous or intravenous
• Dosage: Determined by physician based on hemoglobin levels
• Packaging: Available in pre-filled syringes or vials for accurate dosing
• Storage: Refrigerate at 2°C – 8°C; do not freeze
• Administration: To be used strictly under medical supervision

Boostrix Tdap Vaccine is a reduced-antigen-content diphtheria, tetanus, and acellular pertussis vaccine designed for booster immunization. Manufactured by GlaxoSmithKline Biologicals S.A., Belgium, Boostrix offers effective protection across age groups, including children, adolescents, and adults, and is particularly recommended during pregnancy to protect newborns against pertussis.

Each 0.5 mL dose contains diphtheria toxoid, tetanus toxoid, and three purified pertussis antigens—pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin—adsorbed onto aluminum hydroxide adjuvant to enhance immune response. This reduced antigen formulation is well tolerated while ensuring adequate protection.

Boostrix is supplied in 0.5 mL pre-filled syringes, available as single units or cartons of 10 syringes with package inserts. It is administered by intramuscular injection, preferably into the deltoid muscle. The vaccine can be used as a booster dose after the primary DTP series in children and is also widely used in adult booster programs. In pregnant women, a dose given between 27–36 weeks of gestation provides passive protection to infants in their first months of life.

The vaccine must be stored at 2–8 °C and not frozen. With a shelf life of 36 months, Boostrix is a trusted component of global immunization programs for long-term protection against diphtheria, tetanus, and pertussis.

Tresivac PFS Vaccine, developed by Serum Institute of India Pvt. Ltd., is a combination vaccine designed to protect against three serious infectious diseases: measles, mumps, and rubella. This vaccine is typically administered to infants and children as part of the national immunization program.

The vaccine is presented in a 0.5 ml prefilled syringe, ensuring accurate dosing and ease of administration. It should be stored under refrigeration at 2–8°C and protected from freezing to maintain its efficacy.

Common side effects may include mild local reactions at the injection site, such as redness, swelling, or pain, as well as fever, irritability, and fatigue. These reactions are generally transient and resolve without the need for medical intervention.

Tubervac® BCG Vaccine, manufactured by Serum Institute of India Pvt. Ltd., is a live attenuated vaccine derived from the Moscow strain 361-I of Mycobacterium bovis. It is used for the prevention of tuberculosis (TB), particularly in infants and children in areas where TB is prevalent. The vaccine is administered via an intradermal injection, typically at birth or during early childhood, as part of the national immunization program.

Tubervac® is presented as a freeze-dried powder in a 1 ml glass vial, which is reconstituted with the provided diluent before administration. The vaccine should be stored under refrigeration at 2–8°C and protected from freezing to maintain its efficacy.

Common side effects may include mild local reactions at the injection site, such as redness or swelling. Serious adverse events are rare but should be monitored. It is essential to consult healthcare professionals for proper administration and to follow national immunization guidelines.

AbhayTox Tetanus Toxoid Vaccine is a trusted vaccine used for the active immunization against tetanus, a life-threatening condition caused by Clostridium tetani. Manufactured by Indian Immunologicals Limited, India, this vaccine contains purified tetanus toxoid adsorbed on an aluminum phosphate adjuvant, which enhances immune response. It also contains thiomersal as a preservative to maintain stability.

Each 0.5 mL dose delivers sufficient tetanus toxoid antigen to stimulate protective immunity. The vaccine is available in single-dose glass vials, pre-filled syringes, and 10-dose vials (5 mL) suitable for hospital and public health use. AbhayTox is recommended for children, adolescents, and adults, either as part of the routine immunization program, or as a booster dose every 10 years. It is also widely used in wound management protocols, particularly for contaminated or high-risk injuries, and in maternal and neonatal tetanus prevention programs.

The vaccine is administered via intramuscular injection, usually in the anterolateral thigh for infants or the deltoid muscle for older individuals. It must be stored at 2–8 °C and never frozen. With a shelf life of 36 months, AbhayTox remains one of the most reliable tetanus vaccines, playing a vital role in public health.

• Active Ingredient: 100 mg Etoposide per vial
• Purpose: Used in the treatment of various cancers, including lung cancer, testicular cancer, and lymphomas
• Dosage Form: Injectable, intravenous administration
• Mechanism: Inhibits DNA synthesis, leading to cancer cell death
• Dosage: Determined by oncologist based on patient condition and body surface area
• Packaging: Supplied in vials for IV use
• Storage: Store at 2°C – 8°C; protect from light; do not freeze

Cresp 40 Injection, manufactured by Dr. Reddy's Laboratories Ltd., is a highly effective medication used for the treatment of anemia associated with chronic kidney disease (CKD) and chemotherapy-induced anemia. Its active ingredient, Darbepoetin alfa (40 mcg per 0.4 mL prefilled syringe), is a synthetic form of erythropoietin that stimulates the bone marrow to produce red blood cells, helping improve hemoglobin levels and overall oxygen transport in the body.

Presented in a prefilled glass syringe, Cresp 40 ensures accurate dosing, convenient administration, and safety. It is administered via subcutaneous or intravenous injection, depending on the patient’s condition and doctor’s recommendation. The injection is suitable for adults and children as advised by healthcare professionals.

Proper storage is essential to maintain efficacy: the product should be kept refrigerated at 2–8°C, protected from light, and must not be frozen. The shelf life is 24 months from the date of manufacture. Common side effects include mild hypertension, headache, joint pain, muscle cramps, injection site reactions, and occasional fatigue, while serious adverse events are rare.

Cresp 40 Injection is a vital therapy for improving quality of life in patients suffering from anemia due to CKD or chemotherapy. It is IP/USP compliant and supplied with detailed instructions for safe and effective use, making it a trusted choice for physicians and hospitals.